Drug Shortage Report for HEPARIN SODIUM INJECTION, USP

Last updated on 2025-01-11 History
Report ID 245670
Drug Identification Number 02264315
Brand name HEPARIN SODIUM INJECTION, USP
Common or Proper name HEPARIN SODIUM INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) HEPARIN SODIUM
Strength(s) 1000UNIT
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS
Packaging size 30 mL
ATC code B01AB
ATC description ANTITHROMBOTIC AGENTS
Reason for shortage Other (Please describe in comments)
Anticipated start date 2024-12-18
Actual start date
Estimated end date 2025-01-17
Actual end date 2025-01-10
Shortage status Resolved
Updated date 2025-01-11
Company comments Fresenius Kabi Canada regrets to advise that we will be encountering a supply interruption on our Heparin Sodium Injection, USP 1,000 USP units/mL MD Vial 30 mL effective December 18, 2024, until January 17, 2025.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v6 2025-01-11 English Compare
v5 2025-01-10 French Compare
v4 2025-01-10 English Compare
v3 2024-12-19 English Compare
v2 2024-12-13 French Compare
v1 2024-12-13 English Compare

Showing 1 to 6 of 6